Despite the JAK/STAT pathway is an attractive target for breast cancer therapy due to its frequent activation in breast metatasis, a clinical trial evaluating JAK inhibitors (JAKi, ruxolitinib) in advanced breast cancer failed (NCT01562873). This evidence concerns the gene SOAT1 and breast cancer.